Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Grosset

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|August 19, 2004
Prescribed drugs and neurological complicationsK A Grosset, D G Grosset
Acta Neurologica Scandinavica|March 27, 2013
Inhaled dry powder apomorphine (VR040) for 'off ' periods in Parkinson's disease: an in-clinic double-blind dose ranging studyK A Grosset, N Malek, F Morgan, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 20, 2006
Measuring therapy adherence in Parkinson's disease: a comparison of methodsK A Grosset, I Bone, J L Reid, et al.
European Journal of Neurology|January 29, 2013
Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's diseaseK A Grosset, N Malek, F Morgan, et al.
British Journal of Obstetrics and Gynaecology|October 1, 1989
A study of the experience of Glasgow women in the climacteric yearsD H Barlow, K A Grosset, H Hart, et al.
Acta Neurologica Scandinavica|April 8, 2014
Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic reviewN Malek, D Swallow, K A Grosset, et al.
Parkinsonism & Related Disorders|October 20, 2006
Dopamine agonists and pathological gamblingK A Grosset, D G Grosset, G Macphee, et al.
Acta Neurologica Scandinavica|August 22, 2013
Baseline [(123) I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's diseaseT Nissen, N Malek, K A Grosset, et al.
Scottish Medical Journal|September 25, 2012
Duration of L-dopa and dopamine agonist monotherapy in Parkinson's diseaseT Nissen, E J Newman, K A Grosset, et al.
Acta Neurologica Scandinavica|December 3, 2015
Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patientsN Malek, D M A Swallow, K A Grosset, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Neurology, Neurosurgery, and Psychiatry|August 19, 2004
Prescribed drugs and neurological complicationsK A Grosset, D G Grosset
Acta Neurologica Scandinavica|March 27, 2013
Inhaled dry powder apomorphine (VR040) for 'off ' periods in Parkinson's disease: an in-clinic double-blind dose ranging studyK A Grosset, N Malek, F Morgan, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 20, 2006
Measuring therapy adherence in Parkinson's disease: a comparison of methodsK A Grosset, I Bone, J L Reid, et al.
European Journal of Neurology|January 29, 2013
Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's diseaseK A Grosset, N Malek, F Morgan, et al.
British Journal of Obstetrics and Gynaecology|October 1, 1989
A study of the experience of Glasgow women in the climacteric yearsD H Barlow, K A Grosset, H Hart, et al.
Acta Neurologica Scandinavica|April 8, 2014
Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic reviewN Malek, D Swallow, K A Grosset, et al.
Parkinsonism & Related Disorders|October 20, 2006
Dopamine agonists and pathological gamblingK A Grosset, D G Grosset, G Macphee, et al.
Acta Neurologica Scandinavica|August 22, 2013
Baseline [(123) I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's diseaseT Nissen, N Malek, K A Grosset, et al.
Scottish Medical Journal|September 25, 2012
Duration of L-dopa and dopamine agonist monotherapy in Parkinson's diseaseT Nissen, E J Newman, K A Grosset, et al.
Acta Neurologica Scandinavica|December 3, 2015
Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patientsN Malek, D M A Swallow, K A Grosset, et al.
Pageof 1